Siegel, R. L., et al. (2021). Cancer Statistics, 2021. CA: A cancer journal for clinicians., 71(1), 7–33.
Berk-Krauss, J., et al. (2020). New systematic therapies and trends in cutaneous melanoma deaths among US Whites, 1986–2016. American Journal of Public Health, 110(5), 731–733.
Siegel, R.L., et al., Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. n/a(n/a).
Grob, J. J., et al. (1998). Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases French Cooperative Group on Melanoma. Lancet, 351(9120), 1905–10.
CAS PubMed Article Google Scholar
Davar, D., et al. (2017). High-dose interleukin-2 (HD IL-2) for advanced melanoma: A single center experience from the University of Pittsburgh Cancer Institute. Journal for ImmunoTherapy of Cancer, 5(1), 74.
PubMed PubMed Central Article Google Scholar
Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723.
Robert, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526.
Larkin, J., et al. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535–1546.
Robert, C., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372(4), 320–330.
Weber, J. S., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. The lancet Oncology, 16(4), 375–384.
CAS PubMed Article Google Scholar
Lipson, E. J., et al. (2021). Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224–047). Journal of Clinical Oncology., 39(15_suppl), 9503–9503.
Yap, T. A., et al. (2021). Development of immunotherapy combination strategies in cancer. Cancer Discovery, 11(6), 1368–1397.
CAS PubMed PubMed Central Article Google Scholar
Tawbi, H. A., et al. (2022). Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. New England Journal of Medicine, 386(1), 24–34.
Yatsunenko, T., et al. (2012). Human gut microbiome viewed across age and geography. Nature, 486(7402), 222–227.
CAS PubMed PubMed Central Article Google Scholar
Grice, E. A. (2015). The intersection of microbiome and host at the skin interface: Genomic- and metagenomic-based insights. Genome Research, 25(10), 1514–1520.
CAS PubMed PubMed Central Article Google Scholar
Belkaid, Y., & Segre, J. A. (2014). Dialogue between skin microbiota and immunity. Science, 346(6212), 954–959.
CAS PubMed Article Google Scholar
Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018). The human skin microbiome. Nature Reviews Microbiology, 16(3), 143–155.
CAS PubMed Article Google Scholar
Schadendorf, D., et al. (2018). Melanoma. The Lancet, 392(10151), 971–984.
Feng, H., et al. (2008). Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science, 319(5866), 1096–1100.
CAS PubMed PubMed Central Article Google Scholar
Berman, T. A., & Schiller, J. T. (2017). Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer, 123(12), 2219–2229.
Bazaliński, D., et al. (2017). Marjolin’s ulcer in chronic wounds - review of available literature. Contemp Oncol (Pozn), 21(3), 197–202.
Salava, A., et al. (2016). Skin microbiome in melanomas and melanocytic nevi. European Journal of Dermatology, 26(1), 49–55.
CAS PubMed Article Google Scholar
Mizuhashi, S., et al. (2021). Skin microbiome in acral melanoma: Corynebacterium is associated with advanced melanoma. The Journal of Dermatology, 48(1), e15–e16.
Laihia, J. K., et al. (2010). Protodynamic intracellular acidification by cis-urocanic acid promotes apoptosis of melanoma cells in vitro and in vivo. Journal of Investigative Dermatology, 130(10), 2431–2439.
Naik, S., et al. (2012). Compartmentalized control of skin immunity by resident commensals. Science, 337(6098), 1115–1119.
CAS PubMed PubMed Central Article Google Scholar
Vitiello, G.A. and G. Miller (2020) Targeting the interleukin-17 immune axis for cancer immunotherapy. Journal of Experimental Medicine, 217(1).
Nakatsuji, T., et al. (2018). A commensal strain of Staphylococcus epidermidis protects against skin neoplasia. Science Advances., 4(2), eaao4502.
PubMed PubMed Central Article CAS Google Scholar
Raja, J., et al. (2018). Oncolytic virus immunotherapy: Future prospects for oncology. Journal for ImmunoTherapy of Cancer, 6(1), 140.
PubMed PubMed Central Article Google Scholar
Andtbacka, R. H., et al. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of Clinical Oncology, 33(25), 2780–2788.
CAS PubMed Article Google Scholar
Camara, N.O.S. (2021). Do the gut and skin microbiomes share thoughts on melanoma development? British Journal of Dermatology.
Almeida, A., et al. (2019). A new genomic blueprint of the human gut microbiota. Nature, 568(7753), 499–504.
CAS PubMed PubMed Central Article Google Scholar
Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. PLoS Biol, 14(8), e1002533.
PubMed PubMed Central Article CAS Google Scholar
Li, W., et al. (2019). Gut microbiome and cancer immunotherapy. Cancer Letters, 447, 41–47.
CAS PubMed Article Google Scholar
Louis, P., Hold, G. L., & Flint, H. J. (2014). The gut microbiota, bacterial metabolites and colorectal cancer. Nature Reviews Microbiology, 12(10), 661–672.
CAS PubMed Article Google Scholar
Belkaid, Y., & Hand, T. W. (2014). Role of the microbiota in immunity and inflammation. Cell, 157(1), 121–141.
CAS PubMed PubMed Central Article Google Scholar
Hall, J. A., et al. (2008). Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity, 29(4), 637–649.
CAS PubMed PubMed Central Article Google Scholar
Wu, H. J., & Wu, E. (2012). The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes, 3(1), 4–14.
PubMed PubMed Central Article Google Scholar
Zhou, C. B., Zhou, Y. L., & Fang, J. Y. (2021). Gut microbiota in cancer immune response and immunotherapy. Trends Cancer, 7(7), 647–660.
CAS PubMed Article Google Scholar
Sivan, A., et al. (2015). Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 350(6264), 1084–1089.
CAS PubMed PubMed Central Article Google Scholar
Bessell, C.A., et al. (2020). Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight, 5(8).
Fluckiger, A., et al. (2020). Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science, 369(6506), 936–942.
CAS PubMed Article Google Scholar
Vétizou, M., et al. (2015). Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 350(6264), 1079–1084.
PubMed PubMed Central Article CAS Google Scholar
Matson, V., et al. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 359(6371), 104–108.
CAS PubMed PubMed Central Article Google Scholar
Gopalakrishnan, V., et al. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 359(6371), 97–103.
CAS PubMed Article Google Scholar
Wang, S., et al. (2016). Systematic review: Adverse events of fecal microbiota transplantation. PLoS One, 11(8), e0161174.
PubMed PubMed Central Article CAS Google Scholar
Tanoue, T., et al. (2019). A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature, 565(7741), 600–605.
CAS PubMed Article Google Scholar
Mager, L. F., et al. (2020). Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science, 369(6510), 1481–1489.
留言 (0)